CE marking Catriona Blake Team Manager, Imaging, acute and community care.

Slides:



Advertisements
Similar presentations
And the provisions of….. the Medical Devices Regulations Medical Devices Agency.
Advertisements

Medical Devices The current legislative and administrative structure.
The regulation of medical devices in Australia. Overview Comparing medicines and medical devices What is a medical device? Statistics on patients requiring.
Medical Devices Regulation in the European Union Albuquerque - 10 April 2012 Emmanuel Grimaud Perfea Innovation Lyon, France – Albuquerque, NM
Essential Steps to Safe, Clean Care Essential Steps AIM: Designed as a framework to support local organisations providing and commissioning health and.
Development of ISO standards for AD syringes SIGN Meeting Cambodia, October 2002 Injection technologies G Gerald Verollet.
Agenda The role of MHRA, Hospitals and the Manufacturer
Conformity Assessment Practical Implications InterAgency Committee on Standards Policy June 2007 Gordon Gillerman Conformity Assessment Advisor Homeland.
Options for Regulation and the Impact of Regulation on the Marketplace 29 November 2005 Alan Kent
© Safeguarding public health Implementing Medical Device Regulation and Maintaining Patient Safety Name Nicola Lennard Date October 2011.
© Safeguarding public health BIOABSORBABLE STENTS: REGULATORY ISSUES DR SUSANNE LUDGATE Clinical Director Medicines and Healthcare products Regulatory.
Medical Devices Approval Process
Entering the North American Market
Infection Control Germ Buster Game 1 Infection Control Germ Buster Round 1 2.
CE Marking for Medical Devices “Basic Steps to Compliance” Ján Petrík, PhD. EVPÚ, a.s. Nová Dubnica Medical Devices Branch Office Bratislava 4/27/06 EVPÚ,
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Medical Device Revisions Case Study Phil Brown 20th September 2012.
Weaving regulations into sound value analysis processes Barbara Strain, MA, SM(ASCP) Director Value Management University of Virginia Health System.
ENTERPRISE AND INDUSTRY DIRECTORATE GENERAL European Commission Anna Solé Mena Policy Officer - European Commission DG Enterprise and Industry.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Standardization and Legislation of Medical equipment
New Zealand Medicines and Medical Devices Safety Authority A business unit of the Ministry of Health.
Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 13 GMP Workshop.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Revision of the Medical Device Directives The case of ‘Borderline’ Products used in a self-care context 48th AESGP Annual Meeting Nice, 6-8 June 2012 Laurent.
Slots/Windows of Opportunities HTA – Medical Devices Dr. Wolfgang Ecker EUnetHTA, Rome,
Approximation of legislation to the internal market acquis An EU funded project managed by European Agency for Reconstruction Directive 89/106/EEC on Construction.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Incident Reports and field Safety Corrective Action ( FSCA) Eng. Essam M. Al-Mohandis Executive Director of Surveillance and Biometrics.
Telecommunications Customer Equipment Compliance & Labelling Peter Cunningham Standards Section ITP 2006.
DRUG DEVELOPMENT & REGULATIONS DR ARIF HASHMI. DRUG DEVELOPMENT Discovery and synthesis Preclinical development (chemical testing, biological testing,
Phare SL Implementation of Technical Regulations on Company Level Top Management Seminar Expert: Willem Wolf Chamber of Commerce and Industry,
Changes to the Therapeutic Goods Act and its implications Prepared by: Anna Frazer Prosthetist Hunter Prosthetics & Orthotics Service 10 th November 2006.
1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.
The concept for a network of national Reference Laboratories for high risk IVDs – Results of the working group meeting 1.
© Safeguarding public health Building a sustainable framework for medical devices regulation Graeme Tunbridge Medicines and Healthcare products Regulatory.
Towards ISO Standards for AD syringes: Update from WHO Gerald Verollet World Health Organization 3rd SIGN Meeting - New Delhi.
ABHI Presentation to RCS October MD Regulatory Reform AGENDA EU Council Conclusions June 2011 What Needs Improving Industry Recommendation for New.
New Rules for Clinical Investigations in Germany
The New Approach and GPSD. Council Resolution of 7 May 1985 on a new approach to technical harmonization and standards [OJ C136 of June 1985] New Approach.
Directorate General for Enterprise and Industry European Commission The New Legislative Framework - Market Surveillance UNECE “MARS” Group meeting Bratislava,
Proposal for a Regulation of the European Parliament and of the Council on medical devices and amending Directive 2001/83/EC, Regulation (EC) No 178/2002.
REVISION of IVD DIRECTIVE Regulation instead of Directive.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
The New Legislative Framework
Prof R T KennedyEMC & COMPLIANCE ENGINEERING 1 EET 422 EMC & COMPLIANCE ENGINEERING.
Workshop on conformity assessment procedures and certification of medical devices INT MARKT Kyiv, November 2011 In Vitro Diagnostic Directive.
Care Quality Commission (CQC) Registration. Background The Care Quality Commission (CQC) is the health and social care regulator for England. From 1 April.
TAIEX GPSD Free Movement and Safety Vitomir Fister Beograd,
Introduction to the EU Regulatory system: for general products, and for construction and construction products Dr. Adam Pinney, CPR expert Adam Pinney.
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.
THE OFFICE FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS Responsibility in the handling of medical devices.
Date: in 12 pts MARKET SURVEILLANCE IN THE EU ROLE IN THE NLF - EU ACTIONS and DEVELOPMENTS Rita L'Abbate European Commission DG ENTERPRISE AND INDUSTRY.
Device regulations USA Dr Phil Warner. USA Regulations MEDICAL DEVICES Food, Drug & Cosmetics Act Medical Device Amendments of 1976 (and other things)
Workshop on conformity assessment procedures and certification of medical devices INT MARKT Kyiv, November 2011 Conformity assessment of medical.
Contingent Workforce: Cerner Quality System & Regulations
Flowchart on overview of requirements
The Working Group on Medical Measurements The 23rd Forum Meeting
Regulatory Basics: Europe and the CE Mark
OUS Data: What does the CE Mark Really Mean?
An Integrated Risk Management & Safety Program: IRMSP
Growing need of Clinical Data, PMCF & Registries for Devices Post Market Clinical Follow Up (PMCF) studies are a critical component of the clinical evidence.
The New Legislative Framework Miniseminar New Legal Framework Reykjavík, 10 December 2008 Doris Gradenegger Unit C1: Regulatory Approach for the Free.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
NEW MDR Regulatory Context. NEW MDR Regulatory Context.
Evidence standards for device approval: Regulatory perspectives
The European Association Medical devices
Tobey Clark, Director*, Burlington USA
Difficult to prevent reuse of single use devices
Presentation transcript:

CE marking Catriona Blake Team Manager, Imaging, acute and community care.

EU Regulatory System Notified Body quality systems design dossier clinical data (literature, C/I) accredit audit Competent Authority European market post market surveillance serious adverse events investigation action compliance ERs safety, performance

MHRA’s Regulatory Role Regulation of devices –must meet the Medical Device Regulations 2002 (SI no 618) usually means must be CE marked (covers all Europe) exception are custom made devices –pre-clinical investigation applications –enforcement / compliance action No register of manufacturers

Aims of the MD Directives MD Directives are intended to deliver –a single market –a safe market –via a uniformly applied system To deliver a safe medical device market –the risks must be assessed and managed –pre-market –post-market

Classification System All devices are grouped into one of four classes based on level of risk Class I devices equal lowest risk eg bandage Class III devices equals highest risk eg cardiac ablation catheter

What the Directives do: Directives specify Essential Requirements All devices must conform to essential requirements General: They must be safe and perform as intended. »State of the art. »Benefit over risk. Design and Construction: Chemical, physical and biological properties; infection and microbial contamination; Construction and environmental preparation; protection against radiation, electrical and thermal risks, etc Information supplied by the manufacturer: labels, instructions for use; Instructions for re-processing etc.

What the Directives do: Conformity Assessment Device classification defines how compliance can be demonstrated Class I devices - self declaration by manufacturer All others independently assessed by Notified Body Devices are not approved by MHRA

Post market Surveillance Systems routine continuing appraisal of risk based on post- market experience (ISO/IEC 14971) to –prevent adverse incidents –avert patient or user injury –improve safety & quality of the device and future devices

MHRA Expectations from Manufacturers PMS Analysis & use of research into new techniques & technology (state of the art) Ready access to up-to-date data on product distribution Additional proactive scrutiny of sub-populations & use of post market follow-up studies Proper analysis of adverse events reported to them

New Regulations Possible date 2017

New Regulations MHRA’s key areas that should be improved: the inconsistent performance of Notified Bodies; insufficient clinical evidence relating to the safety and performance of a device before it is placed on the market; imprecise and variable post-market surveillance by manufacturers; the need for traceability of devices to improve vigilance and post-market surveillance; and greater coordination and transparency.

New Regulations European Parliament voted in favour of a number of changes to the proposed regulations including: assessment of some high-risk devices to be undertaken by ‘special’ notified bodies designated by the European Medicines Agency, and an additional case-by-case check by a new expert body – the Assessment Committee for Medical Devices (ACMD); all devices would be considered to be reusable in the absence of scientific evidence supporting a designation as single-use. Where a designation of single-use is approved, reprocessing would not be allowed; making genetic counseling and informed consent mandatory

ANY QUESTIONS?

What do you do? Scenario 1 Patient suffers a cardiac arrest following an over infusion from a Volumetric Pump. The pump was set to infuse at 10ml per hour but after an hour the whole 500mls had gone from the bag. Scenario 2 At midday a new syringe was fitted in the MS26 pump and it was set to deliver the contents of the syringe by midday the following day. The pump was set to 48 mm per 24hours. At midday the following day the syringe was still half full and the pump had stopped.

Points to consider: Quarantine devices Retain infusion sets and any accessories Follow Trusts reporting guidelines e.g. MHRA/NPSA/Coroner Root cause analysis/ Internal investigation

Hot Topics Want more reports on Insulin pumps, needles silicone tracheostomy tubes Misconnections TVT Over the counter HIV test kits